Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Letters

• Publication date

  2007-04-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CANLET.2006.08.004PMID 16996205
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin‐like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma

  2006cited by this paper
• Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.

  2006cited by this paper
• Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling.

  2006cited by this paper
• IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma.

  2006cited by this paper
• The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis.

  2006cited by this paper
• Insulin-Like Growth Factor Binding Protein-2: Contributions of the C-Terminal Domain to Insulin-Like Growth Factor-1 Binding

  2006cited by this paper
• Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.

  2005cited by this paper
• Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor 1-induced activation of extracellular signal-regulated kinase in oral carcinoma cells

  2005cited by this paper
• Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling.

  2005cited by this paper
• Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer

  2004cited by this paper
• Matrix Metalloproteinase-7 Facilitates Insulin-Like Growth Factor Bioavailability through Its Proteinase Activity on Insulin-Like Growth Factor Binding Protein 3

  2004cited by this paper
• IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407.

  2004cited by this paper
• Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer

  2004cited by this paper
• Synthesis and characterization of biotinylated forms of insulin-like growth factor-1: topographical evaluation of the IGF-1/IGFBP-2 AND IGFBP-3 interface.

  2004cited by this paper
• Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells.

  2004cited by this paper
• The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase*

  2004cited by this paper
• What's new in the IGF-binding proteins?

  2004cited by this paper
• In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

  2004cited by this paper
• Epidemiology and Biology of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) as an Anti-cancer Molecule

  2003cited by this paper
• Cellular actions of the insulin-like growth factor binding proteins.

  2002cited by this paper
• Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998.

  2002cited by this paper
• Therapeutic monoclonal antibodies in oncology: an update: Monoclonal antibodies directed at growth factor receptors

  2000cited by this paper
• Monoclonal antibodies directed at growth factor receptors.

  2000cited by this paper
• Tyrosine kinase inhibitor research presses on despite halted clinical trial.

  2000cited by this paper
• Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

  1999cited by this paper
• Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

  1999cited by this paper
• Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3

  1999cited by this paper
• Downmodulation of TGF‐α protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

  1998cited by this paper
• Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

  1998cited by this paper
• Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.

  1998cited by this paper
• Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

  1998cited by this paper
• Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells.

  1996cited by this paper
• The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors.

  1996cited by this paper
• Targeting the epidermal growth factor receptor for therapy of carcinomas.

  1996cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Insulin-like growth factor binding proteins.

  1993cited by this paper
• The insulin-like growth factor family of ligands, receptors, and binding proteins

  1992cited by this paper
• Insulinlike growth factor-binding proteins.

  1990cited by this paper
• Antibodies to human squamous cell carcinoma

  1983cited by this paper
• Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas.

  1981cited by this paper
• A new human cell line (FaDu) from a hypopharyngeal carcinoma

  1972cited by this paper

• Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review).

  2024cites this paper
• LÖKOPLAKİ VE ORAL SKUAMÖZ HÜCRELİ KARSİNOMDA IGF-1R, EZH2, LAMININ-5 EKSPRESYONU EXPRESSIONS OF IGF-1R, EZH2, LAMININ-5 IN LEUKOPLAKIA AND ORAL SQUAMOUS CELL CARCINOMA

  2021cites this paper
• RTKs in pathobiology of head and neck cancers.

  2020cites this paper
• Acquired Resistance to Drugs Targeting Tyrosine Kinases

  2018cites this paper
• Insulin-like growth factor (IGF) axis in cancerogenesis.

  2017cites this paper
• 4 Cell Signalings and the Communications in Head and Neck Cancer

  2017cites this paper
• The value of insulin-like growth factor-1 receptor for predicting early glottic carcinoma response to radiotherapy.

  2016cites this paper
• Emerging Molecular Targets in the Treatment of Head and Neck Squamous Cell Carcinoma

  2016cites this paper
• Type I insulin-like growth factor receptor signaling in hematological malignancies

  2016cites this paper
• Modulation of RTK by sEcad: a putative mechanism for oncogenicity in oropharyngeal SCCs.

  2015cites this paper
• Growth factor receptors: promising drug targets in cancer

  2015cites this paper
• The development of a novel 3D migration assay to study the effects of cell signalling and microenvironment on the migratory behaviour of colorectal cancer

  2015influential citation
• Relationship between insulin‐like growth factor‐1 receptor and human papillomavirus in patients with oropharyngeal cancer

  2015influential citation
• Metformin inhibits histone H2B monoubiquitination and downstream gene transcription in human breast cancer cells

  2014cites this paper
• Overcoming Resistance to EGFR inhibitor in Head and Neck Squamous Cell Carcinoma ( HNSCC )

  2014cites this paper
• A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

  2014cites this paper
• Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit

  2014cites this paper
• Transcriptome profiling of prostate tumor and matched normal samples by RNA-Seq.

  2014cites this paper
• Insulin-Like Growth Factor-1 Receptors in Head and Neck Cancer

  2014influential citation
• Antisense oligonucleotide suppression of human IGF-1R inhibits the growth and survival of in vitro cultured epithelial ovarian cancer cells

  2013cites this paper
• Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.

  2013cites this paper
• Molecular Targeting Drugs for Head and Neck Cancer: EGFR Signaling and its Crosstalk

  2013cites this paper
• The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer

  2013cites this paper
• Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine.

  2013cites this paper
• E-cadherin regulation in ovarian cancer: mechanisms and potential functional roles

  2012influential citation
• Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma.

  2012cites this paper
• Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer

  2012cites this paper
• Acquired resistance to drugs targeting receptor tyrosine kinases.

  2012cites this paper
• Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls

  2012cites this paper
• Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer

  2012cites this paper
• Cetuximab for head and neck cancer: From bench to clinic

  2012cites this paper
• Cell Signalings and the Communications in Head and Neck Cancer

  2012cites this paper
• Development of targeted therapy for squamous cell carcinomas of the head and neck

  2011cites this paper
• Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

  2011cites this paper
• Insulin-like growth factor-1 receptor expression in oral squamous cell carcinoma

  2011cites this paper
• Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells

  2011cites this paper
• Insulin‐like growth factor‐1 receptor inhibitor, AMG‐479, in cetuximab‐refractory head and neck squamous cell carcinoma

  2011cites this paper
• Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent

  2010cites this paper
• Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy.

  2010cites this paper
• Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.

  2010cites this paper
• Defining the pathway to insulin-like growth factor system targeting in cancer.

  2010cites this paper
• Gene alterations in head and neck carcinomas and their role in promoting malignant behavior (Review).

  2010cites this paper
• Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.

  2010cites this paper
• Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer

  2010cites this paper
• Antisense treatment of IGF-IR enhances chemosensitivity in squamous cell carcinomas of the head and neck.

  2010cites this paper
• Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.

  2009cites this paper
• Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival

  2009cites this paper
• Molecular Biology of Head & Neck Cancer: Risks and Pathways

  2009cites this paper
• Molecular biology of head and neck cancer: risks and pathways.

  2008cites this paper
• Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

  2008cites this paper
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials

  2008cites this paper
• IGF-I protects human oral buccal mucosal epithelial cells from sodium nitroprusside-induced apoptosis via PI3-kinase.

  2008influential citation
• Targeting important pathways in head and neck cancer: from the bench to the clinic

  2008cites this paper
• Aberrant kinase signaling: lessons from head and neck cancer.

  2007influential citation
• Molecular Targets in Squamous Cell Carcinoma of the Head and Neck

  2007cites this paper